

B3
concl

medicament which contains the respective humanized monoclonal antibody for protection against thrombotic diseases.

IN THE CLAIMS:

Please cancel claims 4 and 10 without prejudice to, or disclaimer of, the subject matter contained therein.

Please amend claims 1-3, 5, 6, and 11-13 as follows:

B4

1. (Twice Amended) A medicament for protection against thrombotic diseases involving platelet collagen receptor glycoprotein VI (GPVI), comprising at least one active principal that induces an irreversible inactivation or degradation of a GPVI collagen receptor on thrombocytes, wherein the medicament is in the form of a physiologically acceptable injection.

2. (Twice Amended) The medicament as claimed in claim 1, wherein the at least one active principal is an antibody.

3. (Twice Amended) The medicament as claimed in claim 1, wherein the at least one active principal is monoclonal antibody JAQ1.

B5

5. (Twice Amended) The medicament as claimed in claim 1, wherein the at least one active principal is humanized monoclonal antibody JAQ1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

B5
Comp

6. (Twice Amended) A diagnostic agent for the determination of the expression rate of a collagen receptor GPVI, comprising at least one labelled antibody chosen from a monoclonal antibody and a polyclonal antibody, wherein the at least one labelled antibody is directed against a GPVI epitope, and wherein the diagnostic agent is in the form of a physiologically acceptable injection.

B6

11. (Twice Amended) A method for producing a medicament against thrombotic diseases involving platelet collagen receptor glycoprotein VI (GPVI), comprising providing at least one active principal that induces an irreversible inactivation or degradation of a GPVI collagen receptor on thrombocytes, combining the at least one active principal with a physiologically acceptable carrier to form a physiologically acceptable injection medicament.

12. (Twice Amended) The method as claimed in claim 11, wherein the at least one active principal is a monoclonal antibody.

13. (Twice Amended) The method as claimed in claim 11, wherein the at least one active principal is monoclonal antibody JAQ1.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com